Table 2.
Health status of participants with pain and without pain
| Pain group | Pain Free Group | ||
|---|---|---|---|
| Mean ± SD | Mean ± SD | Significance Test | |
| Most recent CD4+ count | n = 16 | n = 56 | |
| cells/microL | 5328.36 ± 206.97 | 338.68 ± 227.55 | t = 0.31; p = 0.75 |
| Time since diagnosis | n = 10 | n = 40 | |
| Years | 4.3 ± 3.3 | 3.8 ± 3.2 | t = 1.01; p = 0.31 |
| Time since initiating treatment | n = 169 | n = 57 | |
| Months | 24.5 ± 22.3 | 21.9 ± 18.1 | t = 0.57; p = 0.57 |
| Number (%) | Number (%) | ||
| Current Clinical Stage (I – IV) | n = 162 | n = 55 | χ 2 = 1.41; p = 0.23 |
| HIV+ (Stage I and II) | 59 (36) | 25 (45) | |
| AIDS (Stage III and IV) | 103 (64) | 30 (55) | |
| Current HIV/AIDS Management | n = 169 | n = 57 | χ 2 = 12.12; p = 0.02 |
| Monitoring | 17 (10.00) | 3 (5.08) | |
| First Line ARVs | 137 (80.59) | 44 (74.58) | |
| Second Line ARVs | 12 (7.06) | 3 (5.08) | |
| Pregnancy Prophylaxis | 2 (1.18) | 4 (6.78) | |
| Defaulted | 1 (0.59) | 3 (5.08) | |
| Opportunistic Infections | |||
| Tuberculosis | 19 (11) | 2 (3) | χ 2 = 3.18; p = 0.07 |
| Candidiasis | 7 (4) | 2 (3) | χ 2 = 0.06; p = 0.8 |
| Other infections (genital herpes, papular pruritic eruptions, meningitis, pneumocystis pneumonia, arthralgia) | 10 (6) | 0 (0) | χ 2 = 3.63; p = 0.06 |